medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 4

<< Back Next >>

Rev Invest Clin 2014; 66 (4)

Impact of eradication of Pseudomonas aeruginosa on survival in Mexican patients with cystic fibrosis

Bustamante AE, Mercado-Longoria R, Tijerina-Menchaca R, Mas-Treviño M, Torres-Rodríguez J

Language: Spanish
References: 31
Page: 307-313
PDF size: 148.56 Kb.


ABSTRACT

Introduction. Patients with cystic fibrosis (CF) present lower airway infection with Pseudomonas aeruginosa. Treatment of initial infection is fundamental to reduce subsequent damage. Material and methods. We evaluated the efficacy of eradication treatment of P. aeruginosa in patients with CF from northeast México using two protocols: inhaled colistin/ oral ciprofloxacin and nebulized tobramycin 300 mg/oral ciprofloxacin. The intervention group included 17 patients with CF and recent infection with P. aeruginosa. The control group consisted of 23 chronically colonized patients of comparable age. Results. Patients received 27 courses of eradication treatment. P. aeruginosa was eradicated in 21/27 (77.77%). The infection free period was 16.9 ± 11.7 months (colistin) and 17 ± 9.7 months (tobramycin) with no statistically significant difference (P = 0.97). Conclusions. Treated patients maintained normal lung function, better nutritional status, and a better chest X-ray score. In the control group 17/23 (73.9%) patients died with no deaths in the study group.


REFERENCES

  1. Castaños C, Rentería F. Fisiopatología de la enfermedad respiratoria. En: Segal E, Fernández A, Rentería F (eds.). Fibrosis quística. Buenos Aires, Argentina: Ediciones Journal; 2004, p. 79-97.

  2. Cystic Fibrosis Foundation. Patient Registry 2009 Annual Data Report. Bethesda, MD Cystic Fibrosis Foundation 2010. Disponible en: www.cff.org.

  3. Nixon GM, Amstrong DS, Carzino R, Carlin JB, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 699-704.

  4. Zhanhai L, Kosorok M, Farrel P, Laxova A, et al. Longitudinal Development of mucoide Pseudomonas aeruginosa infection and lung disease progression in children with Cystic fibrosis. JAMA 2005; 293: 581-8.

  5. Farrell P, Collins J, Broderick L, Rock M, et al Association between Mucoid Pseudomonas infection and bronchiectasis in children with Cystic fibrosis. Radiology 2009; 252: 534-43.

  6. Pressler T, Frederiksen B, Skov M, Garred P, Koch C, Hoiby N. Early rise of anti Pseudomonas antibodies and mucoide phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection. J Cyst Fibrosis 2006; 5: 9-15.

  7. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4: 49-54.

  8. Starner T, Mc Cray P. Pathogenesis of Early Lung disease in cystic fibrosis: A window of opportunity to eradicate bacteria. Ann Intern Med 2005; 143: 816-22.

  9. Taccetti G, Campana S, Festini F, Mascherini M, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-61.

  10. Saiman L, Seigel J. Infection control in cystic fibrosis. Clin Microbiol Rev 2004; 7: 57-71.

  11. Kerem E, Conway S, Elborn S, Heijerman H. Standard of care for patient with cystic fibrosis: An European Consensus. J Cist Fibros 2005; 4: 7-26.

  12. Taylor L, Corey M, Matlow A, Sweezey NB, Ratjen F. Comparison of throat swabs and nasopharyngeal suction specimens in non-sputum-producing patients with cystic fibrosis. Pediatr Pulmonol 2006; 4: 839-43.

  13. ATS/ERS Task Force Standardization of Lung Function Testing: General considerations for lung function testing (2005).

  14. Fisher JJ, Baumon U, Gudowius P, et al. Azitromycin reduces epithelial adherence of P. aeruginosa in patient with cystic fibrosis. Pediatr Pulmonol 1999; S19: S265.

  15. Lee T, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Cyst Fibros 2003; 2: 29-34.

  16. Pittman J, Calloway E, Kiser M, Yeatts J, et al. Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediat Pulmonol 2011; 46: 497-504.

  17. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescent with CF. J Pediatr 2007; 151: 134-9.

  18. Douglas TA, Brennan S, Gard S, Berry L, et al. Acquisition and eradication of P. aeruginosa in young children with CF. Eur Respir J 2009; 33: 305-11.Bustamante AE, et al. Erradicación de Pseudomonas aeruginosa. Rev Invest Clin v n i 2014; 66 (4): 307-313 313

  19. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after Tobramycin solution for inhalation in young children with C. F. Pediatr Pulmonol 2007; 42: 610-23.

  20. Cystic Fibrosis Foundation Evidence based Guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155: S73-S93.

  21. Munk A, Bonacorsi S, Kurkdjian M, Lebourgeuis M, et al. Genotypic characterization of Pseudomonas aeruginosa strains from patient with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001; 32: 288-92.

  22. Emerson J, Rosenfeld M, McNamara S, Ramsey R, Gibson RI. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with CF. Pediatr Pulmonol 2002; 34: 91-100.

  23. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-61.

  24. Ballman M, Rabsch P, Van der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during P. aeruginosa colonization’s in patient with CF. Thorax 1998; 53: 732-7.

  25. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in CF is influenced primarily by Mucoid Pa infection and immune status and only modestly by genotype. Infect Immun 1999; 67: 4744-50.

  26. Gutierrez JP, Grimwood K, Amstrong DS, et al. Interlobar differences in broncoalveolar lavage fluid from children with CF. Eur Respir J 2001; 17: 281-6.

  27. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in Cystic fibrosis: Am J Respir Crit Care Med 2003; 168: 918-51.

  28. Ojeniyi B, Fredericksen B, Hoybi N. Pseudomonas aeruginosa cross infection among patient with CF during a winter camp. Pediatr Pulmonol 2000; 29: 177-81.

  29. Tubbs D, Lenney W, Alcock P, Campbel CA, et al. Pseudomonas aeruginosa in CF: Cross infection and the need for segregation. Respir Med 2001; 95: 147-52.

  30. Farrel PM, Kosorok MR, Rock MJ, et al. Early diagnosis of CF through neonatal screening prevents severe malnutrition and improves long term growth. An Pediatr (Barc) 2001; 107: 1-2.

  31. Mahadeva R, Webb K, Westerbeek R, Carroll N, Dodd M, Bilton D. Lomas Clinical outcome in relation to care in centers specializing in cystic fibrosis. BMJ 1998; 316: 1771-5




2020     |     www.medigraphic.com